Silo Pharma, Inc. Logo

Silo Pharma, Inc.

Develops novel psychedelic & traditional therapies for pain and central nervous system disorders.

SILO | US

Overview

Corporate Details

ISIN(s):
US82711P2011 (+1 more)
LEI:
Country:
United States of America
Address:
677 N. WASHINGTON BLVD, 34236 SARASOTA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company focused on creating novel formulations of traditional and psychedelic therapeutics. The company targets underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. Its portfolio includes programs such as SPC-15 for PTSD and SP-26 for fibromyalgia, as well as preclinical assets for Alzheimer’s disease and multiple sclerosis. Silo Pharma utilizes the streamlined 505(b)(2) regulatory pathway to potentially lower costs and accelerate FDA approval. The company develops its intellectual property through exclusive collaborations with leading universities and research partners.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Silo Pharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Silo Pharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Silo Pharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden
KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America
KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America
KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea
038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea
256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan
4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland
KNRS
Kiniksa Pharmaceuticals International, plc Logo
Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.
United States of America
KNSA
KIORA PHARMACEUTICALS INC Logo
Developing advanced small molecule therapies for vision-threatening retinal diseases.
United States of America
KPRX

Talk to a Data Expert

Have a question? We'll get back to you promptly.